STOCKWATCH
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Quarterly ResultMay 7, 2026, 07:47 AM

Lantheus Q1 Net Income +62% to $118.4M; EPS $1.80; Divests SPECT Business

AI Summary

Lantheus Holdings, Inc. reported a significant increase in net income and diluted EPS for the first quarter of 2026, primarily driven by a substantial gain from the sale of its SPECT business. Net income rose to $118.4 million, up 62% year-over-year, while diluted EPS reached $1.80. Total revenues saw a modest increase to $377.3 million, despite a decline in PYLARIFY sales, offset by growth in DEFINITY and the inclusion of Neuraceq revenue following a 2025 acquisition. The company also recognized a $59.3 million gain from the divestment of its SPECT business.

Key Highlights

  • Divested SPECT business on January 1, 2026, recognizing a $59.3 million gain.
  • Q1 2026 Net Income increased 62.3% to $118.4 million from $72.9 million.
  • Diluted EPS rose 76.5% to $1.80 in Q1 2026 from $1.02.
  • Total revenues grew 1.2% to $377.3 million from $372.8 million.
  • PYLARIFY revenue decreased 6.5% to $240.9 million.
  • DEFINITY revenue increased 6.8% to $84.6 million.
  • Neuraceq revenue was $35.4 million in Q1 2026, not present in Q1 2025.
  • Net cash from operating activities increased 16.3% to $125.1 million.
LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Lantheus Holdings, Inc.

Price Impact